Gedeon Richter acquires Grünenthal's Belara
This article was originally published in Scrip
Gedeon Richter is acquiring Grünenthal's portfolio of oral contraceptives including Belara (chlormadinone acetate plus ethinyl estradiol) for €236.5 million, part of which Richter said it would borrow. The transaction is subject to Germany's antitrust authority's approval which is expected at the end of this year.
You may also be interested in...
Poland's president, Bronislaw Komorowski, has signed a reimbursement bill into the law which will come into force on 1 January.
In the past two years, most multinational pharmaceutical companies announced plans to create production facilities in Russia. They had been ignoring such an opportunity for years, and there were reasons for that. They included risks to investments, administrative barriers, unclear regulations assuming various interpretations and corruption.
Russia's president Dmitriy Medvedev has requested that his government start talks with the US and the EU on the mutual recognition of clinical trial results (including paediatric trials) and prepare proposals for corresponding amendments of existing regulations.